You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • THU0341 Cost Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naïve RA Adult Patients by Anti-Cyclic Citrullinated Peptide-Positive Subgroups

Article info

Article menu
Download PDFPDF
Poster Presentations
Epidemiology, health services and outcome research
THU0341 Cost Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naïve RA Adult Patients by Anti-Cyclic Citrullinated Peptide-Positive Subgroups

Authors

Citation

Alemao E, Schiff M, Johal S, et al
THU0341 Cost Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naïve RA Adult Patients by Anti-Cyclic Citrullinated Peptide-Positive Subgroups
Annals of the Rheumatic Diseases 2015;74:319.

Publication history

  • First published June 9, 2015.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions